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The objectives of this study were to a) replicate our prior finding of a decreased number (Bmax) of platelet
a2-adrenoreceptors in panic disorder, b) determine if binding is also decreased in asymptomatic first-degree
relatives of panic patients (known to be at increased risk for developing panic), and c) evaluate the effect of
treatment on the presumptive decrease in binding (ie, is the decrease a state or a trait marker for panic?). Panic
patients had clonidine and yohimbine platelet-binding assays, symptom ratings, and measurement of lying
and standing plasma epinephrine, norepinephrine, systolic and diastolic blood pressure, and heart rate before
treatment, after approximately 2 months of medication (fluoxetine, tricyclics, or alprazolam) and/or cognitive
behavioral treatment, and after symptom remission while drug free; normal subjects had determinations of the
same measures at approximately the same time intervals. Relatives of both groups had one determination only
of all measures. Tritiated clonidine binding was decreased and lying heart rate was increased in patients
before treatment. Magnitude of binding decrease was correlated with symptom severity and standing
norepinephrine. No binding abnormality was seen in first-degree relatives of patients. Treatment increased
clonidine binding in patients. Both patients and relatives of patients showed significantly increased standing
plasma norepinephrine in comparison to controls. There is a state-related decrease in binding, associated with
symptom severity and norepinephrine, in panic disorder. Abnormal reactivity of norepinephrine to standing
might be a marker for increased likelihood of panic development in individuals at risk.
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INTRODUCTION
Systemic adrenergic abnormalities have been re-
ported in association with stress and with a number
of psychiatric and medical disorders (1). Adrenergic
dysregulation appears especially salient to several of
the anxiety disorders, especially panic disorder (2).
Most of these studies have evaluated individuals
before treatment while symptomatic; only a few have
reported changes during and/or after treatment and
symptom remission as well (3, 4).
Adrenergic functioning in the periphery has been
studied in several ways, such as measurement of
catecholamines or their metabolites and monitoring
of hemodynamic variables. For example, many
groups have studied plasma norepinephrine and
epinephrine and the metabolite 3-methoxy-4-hy-
droxy-phenethyleneglycol (MHPG) in panic patients
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(2, 5-16). We have reviewed these studies (2, 16). A
completely clear picture does not emerge. We have
suggested that:
... if a patient is in a truly basal state, there is
either no increase in catecholamines or only small
catecholamine elevations in panic patients. Pa-
tients, however, may be more reactive to various
'stressful' circumstances (e.g., venipuncture, pos-
tural change, and ambulation) and may have a
response that exceeds the response of control
subjects. . . although not all studies have reported
this (2)
Because adrenergic systems are acutely responsive
to a variety of stimuli and because activity levels can
fluctuate rapidly, attempts have been made to iden-
tify measures that might reflect more stable aspects
of these systems. Furthermore, efforts have been
made to find easily measurable peripheral markers
that reflect some aspect of central nervous system
adrenergic activity. Binding of adrenergic ligands to
peripheral tissues is one such approach. Blood com-
ponents such as lymphocytes and platelets are most
commonly used, in part because of their accessibil-
ity, but also because they have been proposed as
models of neuronal tissue (17, 18).
Changes in drug-free, pretxeatment binding of
platelet a2-adrenergic receptors in panic disorder
have been reported previously, although not all
Psychosomatic Medicine 58:289-301 (1996) 289
0033-31 74/96/5804-O289SO3 00/0
Copyright © 1996 by the American Psychosomatic SocietyO. C. CAMERON et al.
studies have found abnormalities. In two prior stud-
ies of patients with panic disorder, we found de-
creased binding; one study found a decrease with the
antagonist tritiated yohimbine but not with the par-
tial agonist tritiated clonidine, and the other found
decreases with both ligands (9, 11). Another group
(14, 19) also reported decreased yohimbine binding
in panic disorder, but two other groups did not (20,
21). People with both panic and comorbid depres-
sion also had decreased tritiated clonidine binding
(22). Other investigators have found different results
(23, 24), but because they used different ligands, the
studies are not completely comparable. In addition
to changes in panic anxiety, Freedman et al. (25)
reported a decrease in platelet a2-adrenergic recep-
tors, as measured by yohimbine binding, in response
to examination stress in medical students; magni-
tude of decrease was associated with magnitude of
increases in plasma norepinephrine and reported
anxiety.
Despite discrepancies in patterns of ligand bind-
ing abnormality, both of our prior studies found
evidence for decreased binding in symptomatic pa-
tients with panic disorder. The present study was
intended to extend these prior results and to begin to
explore whether adrenergic binding abnormalities
might represent trait markers for either active panic
or panic vulnerability in people at high risk. We had
three aims: a) to replicate our prior finding of de-
creased platelet a2-adrenergic receptor number
(Bmax) as measured with tritiated clonidine and
tritiated yohimbine in panic patients before treat-
ment, b) to determine if there is any abnormality of
binding, systemic catecholamines, or hemodynamic
variables in the asymptomatic first-degree relatives
of panic patients (individuals at high risk to develop
the disorder) (26, 27), and c) to determine the effect
of treatment and symptom reduction on binding in
panic patients, ie, to determine if the previously
described binding abnormality is a state or a trait
marker of panic disorder (28). Both ligands (tritiated
clonidine and tritiated yohimbine) were used be-
cause prior research has suggested that yohimbine,
an antagonist, binds to the total population of plate-
let a2-adrenergic receptors and that clonidine, a
partial agonist, binds to a subpopulation of the
receptors, related to whether the receptors are in an
"active" or an "inactive" (ie, "coupled'V'uncou-
pled," "high affinity'V'low affinity") state (29, 30).
In other words, yohimbine binding should relate to the
total population of receptors present on the tissue
being analyzed, and clonidine binding should reflect a
subpopulation of receptors in the tissue that are in-
volved in the production of a physiological response.
Determinations of anxiety symptoms, lying and
standing plasma catecholamines (epinephrine and
norepinephrine), heart rate, and systolic and dia-
stolic blood pressures were done at the same times as
the binding studies. Relatives of patients and con-
trols were also studied to determine for both patients
and control subjects if there are significant correla-
tions with their respective first-degree relatives for
the dependent variables.
METHODS
Subjects
Patients with panic disorder (with or without agoraphobia),
normal healthy controls, and healthy first-degree relatives of both
groups were studied; no more than one relative of a given patient
or control subject participated. Relatives of patients had no
symptoms of panic attacks. Patients were diagnosed using a
structured interview and DSM-III-R criteria (31); all reached
criteria for panic disorder at the time of initial study (including
having had at least four attacks in the prior 4 weeks, of which at
least two must have been full symptom attacks) and were drug
free for at least 2 weeks before the study. No patient reached
criteria for any affective disorder, and no control subject or
relative reached criteria for any Axis-I disorder as determined
with the structured clinical interview for DSM-III-R SCID-NP
(SCID-nonpatient). All subjects were medically healthy, and no
normal subject or relative was on any medication known to affect
either adrenergic receptors or platelet number or function. Anxi-
ety symptom severity at the time of initial evaluation was quan-
tified by the Hamilton Anxiety Scale (Ham-A, 32), die Symptom
Checklist-90-R (SCL-90-R, 33), and ratings of unexpected and
situational panic attacks and anticipatory anxiety (34). The Ham-
ilton Depression Rating Scale (Ham-D, 35) was also administered
at this time.
Design
The design of the study called for measurements of anxiety
symptoms, platelet membrane a2-adrenergic receptor binding
(Bmax: maximum number of binding sites and Kd: apparent
dissociation constant, for both tritiated clonidine and tritiated
yohimbine), lying and standing plasma epinephrine and norepi-
nephrine, lying and standing systolic and diastolic blood pres-
sure, and lying and standing heart rate in all subjects. The design
involved evaluation of as many patients and control subjects as
possible (but not relatives) through the longitudinal study, includ-
ing determinations on three separate occasions. The follow-up
studies called for the ability and willingness of the subjects to
return for repeat studies and required meeting strict improvement
criteria for patients. Patients were studied initially before treat-
ment (time 1). All of the dependent variables were also measured
in control subjects and in first-degree relatives of patients and
controls. Relatives were only studied once.
Many of the patients and controls subjects had a second
determination (time 2). The second determination of all depen-
dent variables occurred approximately 2 months after the first.
For the patients, this was after 2 months of drug or behavioral
treatment, with the type of treatment determined by clinical
consensus between the patient and his or her treating clinician.
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Some of the patients and normals who had a second determi-
nation also had a third (time 3). For the patients, the third
determination was done after the patient had experienced a
sustained reduction of at least 75% in frequency and severity of
panic attacks and anticipatory anxiety, while being drug free for at
least 1 month. For normal subjects, the third determination was
approximately 1 year after the first, to approximate the length of
time between studies at times 1 and 3 for the patients. For the
third determination, only binding parameters and symptoms were
measured.
Procedure
To control for possible circadian effects (36), all subjects were
studied between 7:30 and 10:30 AM. At the time of arrival in the
laboratory, each subject assumed a supine position and had a
venous catheter inserted for blood sampling. After catheter inser-
tion, the Ham-A and Ham-D rating scales were completed by one
of the investigators (O.G.C.). After 20 minutes supine, an 80-ml
blood sample was obtained. From this specimen, platelets were
isolated for determination of platelet membrane a2-adrenergic
receptor agonist and antagonist binding, and lying plasma cat-
echolamines were determined.
After this specimen was obtained, subjects stood as a mild
autonomic challenge (maintenance of blood pressure with change
in posture), after which a 10-ml specimen was obtained to
measure standing catecholamine levels. Blood pressure (deter-
mined with a stethoscope and sphygmomanometer) and heart rate
(determined by palpation of the radial artery) were measured in
the arm opposite from the catheter immediately before the lying
and standing specimens were obtained.
Twenty four of the patients and all of the other subjects stood
for 3 minutes before the standing specimens were obtained.
Sixteen of the patients stood for 15 minutes; the subjects who
stood for 15 rather than 3 minutes had also been participants in
another study in which both patients and normal subjects stood
for 15 minutes (11). Only platelet binding measures and lying
norepinephrine are reported here for the group of patients studied
at 15 minutes (epinephrine, blood pressure, and heart rate were
not included); standing catecholamine and hemodynamic data are
reported in this study only for the subjects who stood for 3
minutes.
Platelet membrane a2-adrenergic receptor binding assays were
performed by our previously described method (37). Assays were
always performed on fresh membranes on the day on which they
were obtained (never frozen). Specific binding of clonidine, a
partial agonist for the platelet a2-adrenergic receptor, and yohim-
bine, an antagonist, were determined. Specific binding was ap-
proximately 85 to 90%. Estimates of the binding parameters
(Bmax: fmoles/mg protein, and Kd: nM) for both ligands were
made. Plasma for catecholamine assays was frozen at -80°C until
assay. Catecholamines were determined by high performance
liquid chromatography with electrochemical detection (38). Bind-
ing assays and catecholamine determinations were always per-
formed by individuals blind to the subjects' group status.
Data Analysis
Because different numbers of subjects were studied at different
times, separate analyses of variance (ANOVA) were performed
across subject groups at the different time points for the separate
dependent variables (clonidine Bmax and Kd, yohimbine Bmax
and Kd, anxiety severity ratings, and lying and standing epineph-
rine, norepinephrine, systolic blood pressure, diastolic blood
pressure, and heart rate). Effects of different treatment modalities
on binding parameters were evaluated with ANOVA at time 2.
Repeated-measures ANOVA were used to test effects across times.
Tests were done with log-transformed data when appropriate.
Multivariate analysis of variance (MANOVA) was used to evalu-
ate the potentially interacting effects of clonidine Bmax, standing
norepinephrine, and gender. For all tests, significance was de-
fined as p < .05; a trend was defined as p < .10. Significance
levels were reported without adjustment for multiple tests.
Correlations among variables were assessed. Correlations were
determined among all possible combinations of the Bmax for
clonidine and yohimbine, both within and across time points for
times 1 and 2. These correlations were performed to determine if
there was an association between the total number of receptors
and the subpopulation represented by clonidine binding. Binding
parameters were also correlated with Ham-A scores, catechol-
amine levels, and hemodynamic variables. As a test of whether
there is a familial (genetic?) contribution to the values of the
binding parameters, these parameters were correlated for patients
with their first-degree relatives and control subjects with theirs.
Ham-A scores were correlated with Ham-D scores, obtained at the
time of evaluation. Finally, multiple regression was used to
determine the combined association of symptoms and norepi-
nephrine levels with clonidine binding before treatment (time 1).
The first aim (above) was addressed by comparing the results of
the binding parameters of patients vs. asymptomatic individuals
at time 1. The second aim was addressed by comparisons of
binding parameters and other dependent variables for the rela-
tives of the patients. And the third aim was addressed by com-
paring patients to the control subjects at times 2 and 3. A number
of other post hoc issues, such as the status of the catecholamine,
hemodynamic, and symptom variables in patients vs. other sub-
jects across the three times and a number of correlational ques-
tions, was also considered.
RESULTS
A total of 78 subjects were studied. The group size
and gender breakdown were as follows: patients
(male: 11, female: 29), normals (male: 7, female: 13),
relatives of patients (male: 5, female: 4), and relatives
of normals (male: 0, female: 9). Mean ages for the
four groups, respectively, were 34.9, 28.4, 42.0, and
29.0 years. The mean age of panic onset was 24.8
years.
Despite efforts to study all patients and control
subjects across all three time points, some attrition
occurred. Attrition between time 1 and time 2 re-
flected both treatment drop-outs for patients and
some withdrawal from the study for other reasons.
Attrition from time 2 to time 3 mainly reflected the
fact that many patients either did not attain the strict
symptom improvement required or they relapsed
during or soon after discontinuation of active treat-
ment. In actual numbers, 27 of 40 of the patients and
9 of 20 of the control subjects were studied at time 2,
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and, of these, 7 patients and 8 control subjects were
also studied at time 3.
Symptom Ratings
As expected, at time of initial evaluation before
treatment (time 1), patients were highly significantly
more symptomatic than normal controls on several
measures of anxiety symptomatology (Table 1).
Based on the results of the SCL-90-R, this anxiety
severity level was comparable to a large sample of
patients studied previously in this clinic (39).
The mean Ham-D score for patients at evaluation
was 14.3. No subject had a major depressive disor-
der. The correlation at evaluation between the
Ham-D and the Ham-A was +0.910; thus, it is likely
that this Ham-D score represents in large part rating
of anxiety-related symptoms. Only the Ham-A re-
sults were analyzed further.
Symptoms of anxiety in patients decreased from
time 1 to time 2 in response to treatment (Table 2).
There were further decreases from time 2 to time 3 in
the Ham-A and the anticipatory anxiety ratings. At
time 3, the Ham-A rating was approximately 25% of
the rating at time 1 and the anticipatory anxiety
rating was approximately 15% of the rating at time 1.
Across the three times, these decreases were both
highly significant [p < .0005, repeated measures
ANOVA).
Ligand Binding Comparisons
Comparing patients with control subjects (not in-
cluding relatives) at time 1, including gender as well
TABLE 1. Symptom ratings of patients and normal subjects at
the time of evaluation"
TABLE 2. Symptom ratings of patients across times 1 and 2™
Patients Controls p Value
Ham-A 21.7/7.16/20
SCL anxiety 2.16/0.83/14
SCL phobia 1.73/1.3/14
Unexpected 1.56/2.45/18
Situational 3.06/2.96/18
2.6/3.3/33 <.0001
0.17/0.37/22 <.0001
0/0/13 <.0005
0/0/14 <.02
0/0/14 <.0005
Anticipatory 54.2/27.9/19 0.64/3.60/31 <.0001
"Mean/standard deviation/number of subjects studied at time of
evaluation. Ratings of relatives are included in the group of normal
subjects and are not shown separately but were comparable to the
ratings for the normal control subjects. "Unexpected" and "situational"
are the mean number of panic attacks per week of each type.
"Anticipatory" is a rating of amount of time during which anticipatory
anxiety was present on a scale of 0 to 100% for the week before the
rating. Significance ratings are for unpaired t tests. Data were not
available for all subjects.
Ham-A
SCL anxiety
SCL phobia
Unexpected
Situational
Anticipatory
Time 1
21.8/6.50
1.83/0.96
1.24/1.41
1.17/1.47
2.83/2.86
60 2/25.5
Time 2
14.0/4.95
1.03/0.41
0.67/0.39
0.42/0.90
0.17/0.39
26.7/23.1
Subjects (N)
12
6
6
12
12
12
p Value
<.02
<.08
not significant
not significant
<.005
<.001
a Mean/standard deviation. "Unexpected" and "situational" are the
mean number of panic attacks per week of each type. "Anticipatory"
is a rating of average anticipatory anxiety on a scale of 0 to 100% for
the week before the rating. Significance rating are for repeated-
measures ANOVA. Data were not available for all subjects.
as diagnosis as independent variables, there was a
trend for patients to have lower clonidine Bmax (p <
.10, ANOVA); the gender factor was not significant.
For the Bmax for clonidine binding at time 1, an
ANOVA across the normal subjects and the two
relatives groups (without inclusion of patients) did
not approach statistical significance (p = .42); there-
fore, because the binding data among groups were
not significantly correlated (ie, were independent;
see below), these three groups were combined to
form one group of asymptomatic nonpatients for
comparison to the patient group. In comparison with
all of the asymptomatic subjects, patients had signif-
icantly lower clonidine binding (p = .05, ANOVA,
Table 3). In this ANOVA, including gender and
diagnosis, the gender factor was not significant, but
the difference between patients and other subjects
showed an even stronger difference (p < .03). Based
on the estimated w
2 statistic (40), the diagnosis factor
accounts for approximately 4% of the variance in the
data at time 1. No significant differences were ob-
served for yohimbine Bmax (Table 3), and no differ-
ences for the dissociation constants (Kd) were ob-
served for either ligand (not shown). Gender was
also nonsignificant for the other binding measures.
Among the 40 patients, 19 were treated with
medications (fluoxetine 2, tricyclic "antidepressant"
11, and alprazolam 6); the remaining 21 were treated
with cognitive behavior techniques without medica-
tion. For the 27 of these 40 patients who were
studied at time 2, there was a 10.5% increase from
time 1 in the clonidine Bmax (p < .06, repeated
measures ANOVA). Differences among treatment
methods (drug vs. nondrug or among drugs) were
observed for the clonidine Bmax at time 2, although
they were not significant, as measured either as
means at time 2 or as mean change from time 1 to
time 2. For patients treated with drugs, the average
binding across all drugs did not change significantly,
and binding for those given tricyclic drugs actually
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TABLE 3. Binding (Bmax ftnoles/mg protein) to platelet membranes at times 1 to 3°
Time 3
Tritiated clonidine (a2-adrenergic receptor partial agonist)
Patients 24.7/10.4/40 26.7/13.0/27 46.1/19.4/7
Normal subjects 27.8/13.1/20 32.8/12.1/9 30.7/10.0/8
Relatives of patients 30.1/11.3/9
Relatives of normals 34.6/13 0/9
All asymptomatic 29.9/12.7/38
Tritiated yohimbine (a2-adrenergic receptor antagonist)
Patients 102.3/28.0/40 96.9/40.0/27 132.6/46.9/7
Normal subjects 99.2/49.0/20 118.1/55.0/9 112.0/45.7/8
Relatives of patients 84.7/23.6/9
Relatives of normals 96.8/44.0/9
All asymptomatic 95.2/42.5/38
a Mean/standard deviation/number of subjects studied at each time. For both ligands, "all asymptomatic" includes normal subjects and both
relatives groups. Patients were significantly lower than the aggregate group of all asymptomatic individuals at time 1 for clonidine binding (p =
.05, and p < .03 if separated by gender, two-factor ANOVA); there was a trend for patients to be higher than normal subjects for clonidine binding
at times 3 (p < .08, ANOVA).
decreased more than 25%. Individuals treated with-
out medications, however, demonstrated an increase
in binding of more than 20%. Thus, if all patients
were treated nonpharmacologically (thus avoiding
the possible direct effects of tricyclics or other med-
ication on receptor binding), the increase in binding
from time 1 to time 2 would have been even greater
than the increase that was actually observed. The
decrease in clonidine binding observed with tricy-
clic drugs was not observed for yohimbine binding;
there was no consistent difference for patients
treated with vs. without medication for change in
yohimbine binding from time 1 to time 2. The
normal subjects also showed an increase in binding
from time 1 to time 2 of comparable magnitude,
however. Thus, because of unexpectedly low
clonidine binding for some of the control subjects at
time 1 and the increase from time 1 to time 2 for
these control subjects, the change in binding from
time 1 to time 2 observed in the patients cannot be
ascribed unequivocally to clinical improvement.
Seven of the patients and eight of the control
subjects were studied a third time; all patients were
drug free and had substantially improved clinically
at that time. The patients showed a substantial
further increase in clonidine binding (Bmax) at that
time [p < .09, repeated measures ANOVA for time 2
to time 3, Table 3), and the control subjects did not
show an increase from time 2 to time 3. Comparing
time 3 only, patients showed a trend for binding to
be higher than for the normal subjects (p < .08,
ANOVA); based on the estimated w
2 statistic, this
difference accounts for approximately 16% of the
variance in the data at time 3.
Ligand Binding Correlation
To evaluate the relationships among the binding
parameters themselves, correlations were deter-
mined among all possible combinations of the Bmax
for clonidine and yohimbine at times 1 and 2. All
were positive and significant except the clonidine
binding at time 2 with the binding of both of the
ligands at time 1 (Table 4).
Symptom ratings were correlated with binding
parameters. At time 1, for all subjects combined, the
correlation of the clonidine Bmax with the Ham-A
TABLE 4. Pearson product-moment correlations among the binding measures (Bmax) at times 1 and 2
Yoh-T1 Clon-T1 Clon-T2
Yoh-T1
Yoh-T2
Clon-TI
Clon-T2
1.0
+0.504
N = 36, p<.01
+0.450
N = 78, p < .001
+0.082
N = 47, not significant
—
1.0
+ 0.395
N = 36, p < .05
+ 0.456
N = 36, p < .01
—
1.0
+0.186
N = 47, not significant
Yoh, yohimbine; Clon, clonidine; T1, time 1 (before treatment); T2, time 2 (after approximately 2 months of treatment or similar interval for
controls).
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was -.270 and with the rating of anticipatory anxi-
ety was -.281 (both p = .05). When these same
correlations were calculated for patients only, the
correlation coefficients were —.499 (p < .04) and
— .406 [p < .08), respectively. These results indicate
that, before treatment, higher symptom ratings were
associated with lower clonidine binding. Other
binding parameters did not show significant corre-
lations with symptom severity. Changes in clonidine
Bmax from time 1 to time 2 were not significantly
correlated with changes in symptom ratings; this is
perhaps due in part to the fact that different treat-
ment methods were associated with different effects
on clonidine binding.
Familial Effects
To determine if there were familial effects on
binding, correlations were determined for the four
binding parameters (clonidine and yohimbine Bmax
and Kd) for all subjects with their first-degree rela-
tives and separately for patients with their first-
degree relatives and normal subjects with their first-
degree relatives. For all subjects combined, the
magnitudes of the coefficients ranged from +0.086 to
+0.318; none was significant. Results for the patient
and the normal subject groups done separately were
comparable with the results of the combined group
and again were not significant.
Catecholamines
Comparisons were performed for catecholamines;
standing comparisons included only the patients
who stood for 3 minutes (Table 5). Across the four
groups, at time 1 there was a significant difference
for standing norepinephrine (Fig. 1). This was due to
higher levels for both patients and relatives of pa-
tients than for the other two groups [p < .02,
ANOVA); this difference remained, with the same
significance level, when differences in log-trans-
formed standing norepinephrine levels were com-
pared. Based on post hoc tests, patients were signif-
icantly different than controls, and relatives of
patients were different than both controls and rela-
tives of controls. For the first two groups, there was
a mean increase of 47% (44% for patients and 54%
for relatives of patients) from lying to standing, and
for the other two groups, the increase was only 21%
(15% for normals and 29% for relatives of normals).
Across the four groups, in addition to absolute val-
ues, there was a trend toward a significant difference
[p < .08, ANOVA) for change scores (ie, the differ-
TABLE 5. Lying and standing norepinephrine and
epinephrine (pg/ml), systolic and diastolic blood pressure (mm
Hg), and heart rate (bpm) in patients vs. all other subjects at
times 1 and 2°
Lying norepinephrine
Patient
Other
Standing norepinephrine
Patient
Other
Lying epinephrine
Patient
Other
Standing epinephrine
Patient
Other
Lying systolic blood pressure
Patient
Other
Standing systolic blood pressure
Patient
Other
Lying diastolic blood pressure
Patient
Other
Standing diastolic blood pressure
Patient
Other
Lying heart rate
Patient
Other
Standing heart rate
Patient
Other
Time 1
291/126/35
309/159/28
487/166/18
420/214/27
145/271/19
218/471/28
131/161/18
154/228/27
115/14.5/23
114/14.2/36
109/13.9/22
108/17.7/33
73.4/12.9/23
67.4/10.2/36
78.2/14.6/21
73.5/17.3/32
73.4/14.0/23
67/10.2/36
83.5/17.9/22
79.6/11.3/34
Time 2
252/142/26
332/125/8
448/244/11
486/190/8
127/161/14
139/93/8
126/114/11
142/84/8
110/12.6/18
110/10.8/9
102/16.9/15
107/17.6/9
70.1/11.7/18
66.4/9.68/9
72.8/11.2/14
74.6/18.6/9
75.3/14.2/18
68.1/9.65/9
90.3/18.3/15
80.1/11/9
3 Mean/standard deviation/number of subjects studied at each time.
Data, presented only for subjects who stood 3 minutes, were not
available for all subjects at all time points. Lying heart rate was
significantly higher in patients than in other subjects at time 1 (p < .05,
ANOVA), and lying diastolic blood pressure showed a trend in the
same direction (p < .06, ANOVA). See Figure 1 for standing norepi-
nephrine presented separately for each of the four groups.
ence between lying and standing norepinephrine);
the significance level was the same (p < .08,
ANOVA) for a change-score comparison for patients
vs. controls only (excluding relatives). The mean
standing norepinephrine levels for the four groups
were: patients 487 pg/ml, relatives of patients 628
pg/ml, controls 346 pg/ml, and relatives of controls
381 pg/ml. No other catecholamine differences were
observed (Table 5), and no gender differences were
seen. Comparing patients with controls only (with-
out inclusion of data from relatives), patients were
significantly higher for absolute level (p < .03,
ANOVA), and there was a trend in the same direc-
tion for change scores (standing minus lying, p <
.08, ANOVA). Absolute values for standing levels
showed more robust differences than change scores
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800 -i
Pt-Rel Con Con-Rel
Subject Group
Fig. 1. Plasma norepinephrine (mean ± SEM), after 20 minutes
lying [black bars) followed by 3 minutes standing [open
bars), for panic patients [Pt, N = 18), healthy asymptom-
atic first-degree relatives of the patients [Pt-Rel, N = 6),
healthy control subjects [Con, N = 12), and healthy
first-degree relatives of the control subjects [Con-Rel,
N = 9). There were no significant differences across lying
levels; there was a significant difference across standing
levels, with patients significantly greater than controls
and relatives of patients significantly greater than both
controls and relatives of controls. Only subjects who had
both lying and standing levels are presented.
because lying levels were somewhat higher for pa-
tients and their relatives (Fig. 1).
At time 1, standing norepinephrine was signifi-
cantly negatively correlated with clonidine binding
(r = -.389, p < .01). A significant correlation was
also observed with standing norepinephrine and
yohimbine binding (r = -.385, p < .01). No other
significant correlations were observed for any cate-
cholamine levels with any of the binding parame-
ters. No significant correlations were observed for
any of the catecholamine levels with any of the
symptom ratings at time 1. Age was not significantly
correlated with clonidine or yohimbine Bmax or Kd
at time 1. There were trends for age to be signifi-
cantly correlated with lying norepinephrine at time
1 (r = +.411, p < .06) and with standing (r = +.400,
p < .08).
To evaluate the possible effects at time 1 of stand-
ing norepinephrine and gender on the group differ-
ences in clonidine Bmax, MANOVA were per-
formed. Including clonidine Bmax and standing
norepinephrine for patients vs. all other subjects, the
overall MANOVA was significant (p = .05); in this
MANOVA, norepinephrine was significantly differ-
ent across groups (p < .04), and there was a trend for
Bmax (p < .08). In a similar MANOVA, but also
including gender as a between-subject factor, the
overall MANOVA remained significant for patients
vs. other subjects (p < .04) but was not significant for
gender; norepinephrine was slightly more strongly
significant (p < .03), and a more robust trend was
observed for Bmax (p < .06). Thus, differences
between patients vs. other subjects in norepineph-
rine level produced only a small effect on the differ-
ence in clonidine binding in patients vs. asymptom-
atic individuals.
To further assess the relationship between vari-
ables found individually to be of significance, mul-
tiple regressions were performed using standing nor-
epinephrine and symptom rating (Ham-A) to predict
clonidine Bmax at time 1. These regressions were
performed for all subjects, for patients only, and for
all other subjects only (Table 6). When all subjects
and both independent variables were included, the
multiple regression was significant, and norepineph-
rine was a more strongly associated predictor than
symptoms. In the multiple regression including pa-
tients only, the overall regression was of greater
magnitude than the regression for all subjects (but
TABLE 6. Results of multiple regressions including time 1 standing norepinephrine and anxiety symptoms (Ham-A) as predictors
of time 1 chlonidine Bmax"
All subjects
Pts only
Nonpatients
R
.424
.533
.416
Multiple Rej
df
40
14
25
;ression
p Value
0.023
0.135
0.113
Factor
NE
Sxs
NE
Sxs
NE
Sxs
Partial Correlations
r
-.346
-.225
-.242
-.493
-.398
+ .064
p Value
0.024
0.135
0.343
0.067
0.052
0.746
+ .062
-.075
-.211
NE, standing norepinephrine; Sxs, symptoms (Ham-A).
" Only subjects who stood for 3 minutes are included.
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was not significant because of the smaller number of
subjects); the partial r for symptoms showed a trend
toward significance, and the partial r for norepi-
nephrine was much weaker. In contrast, in the mul-
tiple regression including other subjects only (non-
patients), the overall multiple-R was of comparable
magnitude to the multiple regression for all subjects
(again not significant because of the smaller number
of subjects), but the partial r for norepinephrine
approached significance, and the partial r for symp-
toms was very weak. For all three groups (all sub-
jects, patients only, and nonpatients only), the cor-
relations between standing norepinephrine and
symptoms were very weak. These results suggest
that symptoms and standing norepinephrine make
separate, independent contributions to the predic-
tion of clonidine binding and that the two variables
are relevant in different populations. In patients,
symptoms were a strong predictor, and standing
norepinephrine was less important, but standing
norepinephrine was a fairly strong predictor, and
symptoms made no contribution to prediction in
nonpatients.
There were no lying or standing norepinephrine
differences for patients vs. control subjects at time
2. Across groups of patients receiving different
treatments at time 2, there were significant differ-
ences in lying (p < .001, ANOVA) and standing
(p < .01, ANOVA) norepinephrine; as expected,
based on prior studies (9, 41, 42), the highest
levels were for those patients who received a
tricyclic drug. Tricyclic drugs produced approxi-
mately 60% increases in norepinephrine from time
1 to time 2; the other drugs produced smaller
increases or small decreases.
Hemodynamics
Lying heart rate was higher in patients than in
other subjects at time 1 (p < .05, ANOVA, Table 5),
and lying diastolic blood pressure at time 1
showed a trend in the same direction (p < .06,
ANOVA, Table 5). Unlike the standing norepi-
nephrine data, relatives of patients showed no
significant differences in hemodynamic variables
from controls or relatives of controls. No other
measurements were significantly different at any
time, and generally there did not appear to be any
systematic differences. For patients, there was an
association between norepinephrine and heart
rate; this association was not observed for the
other groups nor was any other consistent pattern
of association.
DISCUSSION
This study was designed to address three ques-
tions: a) Could the finding of decreased platelet
a2-adrenergic receptor binding in people with active
panic disorder be replicated? b) Do asymptomatic
first-degree relatives of panic patients also have
decreased binding? and c) Does the putative de-
creased binding in panic patients remain or normal-
ize in response to effective treatment (ie, is this
decreased binding a state or a trait abnormality in
these patients)? Plasma catecholamine levels, hemo-
dynamic variables, and anxiety symptoms were also
evaluated in relation to these three questions.
Concerning the first question, in comparison to the
nonsymptomatic individuals in the study, panic
patients had a significantly decreased maximum
number of binding sites (Bmax) for the partial ago-
nist clonidine, although the effect only accounted for
a small amount of the variance. The magnitude of
this decrease was significantly negatively correlated
with symptom severity, indicating that the most
symptomatic patients had the greatest decreases in
binding in comparison with asymptomatic individ-
uals. No differences in the Bmax for the antagonist
yohimbine or the Kd for either ligand were observed.
As described above, several groups have evaluated
platelet a2-adrenergic receptor binding to platelets
in panic disorder. We have reported decreases in two
prior studies (9, 11), as has one other group (14, 19),
and other studies did not report differences (20, 21).
In one of our prior studies, only a decrease in
yohimbine Bmax was observed (9), and in the other,
decreases in binding for both ligands were seen (11).
In the present study, a decrease in clonidine binding
was seen, but the Bmax for yohimbine was not
abnormal. A clear explanation for the discrepant
results across studies is not apparent; differences in
methodology (eg, ligand used) and characteristics of
the subjects studied (eg, prior treatment history,
presence and severity of comorbid disorders such as
depression) are likely to account for at least part of
the difference. In the three studies reported by our
group, the results of each study were a little differ-
ent, but in all three evidence for a decrease in
platelet membrane a2-adrenergic receptor number
was obtained. Two out of three of our studies
showed decreases for yohimbine, and two of three
showed decreases for clonidine. Of particular inter-
est is the result with the clonidine because we are
the only group that has systematically investigated
agonist binding (9, 11, 22).
It was observed that the binding measures for
some of the normal subjects were unexpectedly low
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at time 1 in comparison with the results from our
two prior studies, despite identical binding assay
techniques (the binding parameters were more con-
sistent with prior results for these subjects at times 2
and 3). It is not clear why this occurred. Because no
verifiable explanation could be found to account for
this result, these subjects were not excluded from the
analysis. Had this unexpectedly low binding for
some of the normal subjects not occurred, the differ-
ence between patients and nonsymptomatic individ-
uals at time 1 would have been greater.
In addition to the finding of low clonidine Bmax at
time 1 for some of the normal subjects, there was a
"drift" in assay results (ie, across subjects studied at
times 1 and 2, later results were higher than earlier
results in normal subjects, in whom conditions
across time did not change). This was partially, but
not completely, explained by the unusually low
binding for the subgroup of normal subjects de-
scribed above. This is an important methodological
issue; if we had not studied both experimental and
control groups at the same time, it would not have
been possible to determine that such assay "drift"
had occurred. These differences might have been
attributed erroneously to differences among groups.
In all studies of this kind, all experimental groups
should be evaluated simultaneously to avoid cohort
effects. This is also of potential importance because
there might be circannual changes in binding; this
apparently has not been studied previously. Even if
such a fluctuation exists, however, it should not
affect our data because subjects in all four groups
were studied over many months.
Standing norepinephrine levels at time 1 were
higher for panic patients than for normal subjects
and were negatively correlated with the number of
binding sites for both ligands at time 1; the lying
norepinephrine levels were not significantly differ-
ent, but trends in the same direction for the negative
correlation with the clonidine Bmax were observed
for the lying norepinephrine levels (not shown). The
negative relationship between standing norepineph-
rine and clonidine binding was present for both
patients and nonpatients but was more robust for
nonpatients. Lying heart rate was increased in pa-
tients, and a trend for increased lying diastolic blood
pressure was observed; standing heart rate and
standing diastolic blood pressure was also higher in
patients but not significantly so. Norepinephrine
levels were related to heart rate but only in patients.
These results are consistent with increased pe-
ripheral adrenergic activity in patients in this study.
The result with norepinephrine is specifically con-
sistent with the hypothesis that patients have normal
basal levels but show increased reactivity to an
adrenergic challenge (upright posture). Furthermore,
the negative correlation between standing norepi-
nephrine and binding is consistent with the hypoth-
esis that catecholamine increases might produce
"down-regulatory" decreases in clonidine binding.
Against this interpretation, however: a) This nega-
tive correlation was not observed in our prior study
(11); b) in the present study, the correlation was
more robust for nonpatients than for patients; and (c)
in general (as noted above), there have not been
consistent findings concerning the status of systemic
norepinephrine levels in panic patients. One possi-
ble explanation for the discrepant norepinephrine
results reported previously might relate to the dy-
namics of norepinephrine release. For example,
Stein et al. (12) found that norepinephrine levels 5
minutes after standing were normal in panic patients
but that the heart rate increase was greater in pa-
tients. An inspection of their data (their Fig. 1)
reveals that the heart rate increase (ie, the autonomic
response) was apparent by 75 seconds after standing.
In the present study, we measured standing norepi-
nephrine 3 rather than 5 minutes after subjects
stood. It is possible that patients, upon standing,
released norepinephrine into the systemic circula-
tion more rapidly than control subjects but did not
attain a higher final level. In other words, reactivity
was abnormal. A continuous multiple-sampling pro-
cedure will be needed to resolve this specific ques-
tion, and, in general, in future studies investigators
must attend closely to reactivity and timing issues
and to determination of whether subjects have at-
tained a reliable, stable baseline. As an example,
despite efforts in the present study to obtain a valid
basal lying catecholamine level, both patients and
their relatives were slightly higher than the control
subjects and their relatives (Fig. 1). Although there
are a number of possible reasons for this difference
(including the possibility that it was due to chance
variation only), it might reflect the fact that people
with panic or people who are at risk for panic are in
general more reactive to a wide variety of factors and
situations.
Concerning the second question, there were no
significant differences between binding parameters
for normal subjects or their relatives compared with
first-degree relatives of individuals with panic dis-
order. Furthermore, unlike the prior report of a
significant correlation for the Bmax for yohimbine in
dizygotic twins (43), there were no significant corre-
lations for any of the binding parameters for either
patients or normal subjects with their respective
first-degree relatives in this study.
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Standing norepinephrine levels were elevated
both in patients and in the asymptomatic relatives of
patients in comparison with normal subjects and
their relatives. It is known that these first-degree
relatives of panic patients are at increased risk for
the development of panic disorder, so these data
suggest that the increase in plasma norepinephrine
in response to a postural challenge might be a
biological marker for risk of development of panic, at
least in individuals with relatives who have the
disorder. Although this finding was not hypothe-
sized and the sample was small, and thus this
finding must be interpreted cautiously, if valid it
would be the first biological marker of people at risk
but not symptomatic for an anxiety disorder. Such a
marker would be extremely valuable for several
kinds of studies because it would facilitate the pro-
spective study of individuals perhaps most likely to
develop panic before the presence of attacks them-
selves and before their sequellae confound interpre-
tation of study results.
Concerning the third question, the difference in
clonidine binding for patients vs. control subjects
diminished over time in response to panic treatment,
such that by time 3, binding for patients was actually
higher than for normal subjects. There was no con-
sistent pattern of change for the other binding pa-
rameters over the three times. These results suggest
that binding might actually be increased in people
with panic disorder when they do not have active
panic in comparison with normal subjects but that
the presence of the attacks themselves leads to a
decrease in binding so that it appears that panic
disorder produces a decrease in binding. Verifica-
tion of the finding that binding is increased in panic
disorder, independent of the occurrence of the at-
tacks themselves and of possible drug effects on
binding, will require further research.
Patients treated without medication showed a
greater rise in the clonidine Bmax in response to
treatment than did patients treated with one of the
medications used. In contrast, treatment with tricy-
clic "antidepressant" drugs actually increased nor-
epinephrine levels, as has been previously reported
(9, 41, 42), and was associated with decreased
clonidine binding, as we have reported previously
(9). Unlike the present study, in this prior study,
decreased yohimbine binding was also observed.
However, in the prior study also, the effect of a
tricyclic drug was greater for clonidine than for
yohimbine binding. Anxiety symptoms decreased in
response to treatment, but these decreases were not
significantly correlated with the changes in
clonidine Bmax.
In general, the number of binding sites (Bmax) for
the two ligands was positively correlated within and
across times 1 and 2. This indicates that the number
of sites that bind clonidine is a relatively stable
percentage of the total number of binding sites (ie,
the number of sites that bind yohimbine). The ex-
ception was the Bmax for clonidine at time 2, which
was only weakly correlated with the clonidine and
yohimbine binding at time 1. This is consistent with
the hypothesis that treatment has effects not on the
total number of binding sites (in this study, the Bmax
for yohimbine did not significantly change in re-
sponse to treatment) but rather on the subpopulation
of sites that are physiologically active (ie, "coupled"
or "high affinity" sites, the clonidine sites) and thus
perhaps more relevant to the pathophysiology of the
active disorder.
As already noted, the decreased Bmax for
clonidine observed in panic patients disappeared in
response to treatment. Furthermore, first-degree rel-
atives of panic patients did not have decreased
binding. Together, these results are consistent with
the conclusion that a decreased number of platelet
membrane a2-adrenergic receptors is a state rather
than a trait marker for panic disorder. Many prior
studies (eg, 21, 44-46), but not all (eg, 47), have also
demonstrated lower binding or functional activity of
beta adrenergic receptors on lymphocytes in panic
patients, and the results of one study have indicated
that the beta adrenergic receptor is also a state
marker of panic (3); in this prior study, however, the
patients were never evaluated after treatment while
drug free.
To summarize the answers to the three aims of this
study: First, there is a decrease in the number of
a2-adrenergic receptors for the partial agonist
clonidine to platelet membranes in panic patients;
this decrease is associated with anxiety severity and,
to a lesser extent, to reactivity of systemic norepi-
nephrine to an adrenergic challenge (standing). Sec-
ond, asymptomatic relatives of panic patients have
normal binding parameters but might have another
abnormality of adrenergic function (that is, in-
creased adrenergic reactivity to a postural challenge
as indicated by a greater increase in norepineph-
rine). And, third, based on the normality of binding
in relatives of patients and the increase in binding in
response to treatment, the binding abnormality ap-
pears to be a state rather than a trait marker of panic
disorder. In contrast to the evidence that the binding
abnormality is a state marker, the finding of the
increased standing norepinephrine in both panic
patients and their at-risk relatives suggests that the
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standing norepinephrine increase, if replicated,
might represent a trait marker for a panic diathesis.
Binding was not correlated with age, and gender
was not found to be a significant contributor to
binding. Menstrual cycle and time of year of study
were not specifically controlled or addressed. Most
prior studies indicate that age (36, 48-50), gender
(51), menstrual cycle (52-55), and circadian factors
(36, 48) do not affect platelet a2-adrenoreceptor
binding, although a few investigators have reported
effects for age (56), gender (48), and menstrual cycle
(48). There do not appear to be any studies of
potential circannual effects.
What might be the mechanism producing this
abnormality in panic disorder? One prior genetic
linkage study found no evidence for mutations in
several gene loci for adrenergic receptors, including
the a2-adrenergic receptor, in pedigrees of families
with panic (57). This result seems consistent with
our finding that the binding abnormality is a state
rather than a trait marker for panic. Furthermore, the
finding that the abnormality in this study was for
clonidine binding, but not for yohimbine binding, is
consistent with the hypothesis that the abnormality
is not for the total number of platelet receptors but
rather for those that are functionally active. Finally,
there were significant correlations of pretreatment
clonidine binding with symptom severity and nor-
epinephrine reactivity. All of these findings are
consistent with the hypothesis that the platelet bind-
ing abnormality is associated with active panic dis-
order.
It seems unlikely that the status of a receptor on
platelets could produce or cause panic attacks. Thus,
it might seem that the decrease in clonidine binding
is a result of panic rather than related to the patho-
physiology or cause. Down-regulation of receptors
secondary to increases in circulating catecholamines
would be the likely mechanism (11, 36). The nega-
tive correlation of pretreatment binding with norepi-
nephrine reactivity seen in this study for both pa-
tients and nonpatients is consistent with the
hypothesis of down-regulation. Against this mecha-
nism as a possible explanation for decreased binding
in patients is the fact that our prior study did not
find this inverse relationship (11), and prior research
in general has produced ambiguous results concern-
ing abnormalities of systemic catecholamine levels
in panic (2, 11, 16). However, we have suggested
previously that abnormalities of adrenergic reactiv-
ity have not been carefully evaluated in most prior
research (2, 16). Thus, an abnormality of adrenergic
reactivity, leading to intermittent increases in
plasma catecholamines in panic patients either dur-
ing panic attacks or at other times, and a consequent
decrease in the number of platelet a2-adrenergic
receptors could be the mechanism of this abnormal-
ity. Further research is needed concerning possible
abnormalities of adrenergic reactivity in panic dis-
order.
Another possibility is that there is an abnormality
of «2-adrenergic receptor function in the central
nervous system that is causally related to the patho-
physiology of panic and that the status of the platelet
a2 -adrenergic receptor is correlated with this central
nervous system abnormality. Thus, an important
question is the relevance of the status of peripheral
markers of a disorder to the central nervous system
pathophysiology of the disorder. One marker of
central nervous system adrenergic functioning, the
growth hormone response to clonidine, has been
shown repeatedly to be blunted in panic disorder (2).
An issue of major importance would be to determine
whether these two markers of a2-adrenergic receptor
status in panic, one in the periphery and one in the
central nervous system, are related to each other. An
association of this kind would link the status of the
platelet receptor directly to the pathophysiology of
the disorder, rather than it being merely a result of
panic.
Finally, for both research and clinical purposes, it
would be very useful to have a marker of abnormal
central nervous system functioning that is as easily
accessible as the platelet, not only for panic disorder
but also to study stress and other psychiatric disor-
ders (58, 59). For example, many studies of platelet
a2-adrenergic receptor binding and the growth hor-
mone response to clonidine have already been re-
ported in depression (60, 61), but here also the
potential relationship between these markers is not
known. One final issue related to clonidine, both as
a binding ligand and as a drug producing various
physiological effects, is the observation that
clonidine can react with nonadrenergic imidazoline
receptors; thus, it is possible that whatever
clonidine-associated abnormalities are observed in
panic, depression, or other disorders might not be
related to adrenergic or noradrenergic dysfunction
(62).
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